利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.051 秒)

    Composition for treatment of cervix cancer
    3.
    发明授权
    Composition for treatment of cervix cancer 有权
    用于治疗子宫颈癌的组合物

    公开(公告)号：US08377899B2

    公开(公告)日：2013-02-19

    申请号：US12513337

    申请日：2007-11-05

    申请人： Young Kee Shin ,  Hun Soon Jung ,  Yu Kyoung Oh

    发明人： Young Kee Shin ,  Hun Soon Jung ,  Yu Kyoung Oh

    IPC分类号： C12N15/113

    CPC分类号： C12N15/1131 ,  C12N2310/14 ,  C12N2320/31

    摘要： The present invention relates to a composition for the treatment of cervix cancer, more precisely a composition for the treatment of cervix cancer comprising the first active part containing human papilloma virus (referred as “HPV” hereinafter) specific siRNA as an active ingredient and the second active part containing an anticancer agent as an active ingredient. The composition for the treatment of cancer of the present invention has better anticancer effect than the single therapy of the HPV specific siRNA or the anticancer agent, and has an advantage of reducing side effects by using the anticancer agent at a low concentration.

    摘要翻译： 本发明涉及用于治疗子宫颈癌的组合物，更确切地说，涉及用于宫颈癌治疗的组合物，其包含含有人乳头状瘤病毒（以下称为HPV）特异性siRNA作为有效成分的第一活性成分，第二活性部分 含有抗癌剂作为活性成分。 本发明的癌症治疗用组合物与HPV特异性siRNA或抗癌剂的单一疗法相比具有更好的抗癌作用，具有通过低浓度使用抗癌剂而降低副作用的优点。

    METHOD TO INHIBIT CANCER TARGETING CD24
    4.
    发明申请
    METHOD TO INHIBIT CANCER TARGETING CD24 有权
    禁止癌症靶向CD24的方法

    公开(公告)号：US20100166649A1

    公开(公告)日：2010-07-01

    申请号：US12307108

    申请日：2007-07-02

    申请人： Young Kee Shin

    发明人： Young Kee Shin

    IPC分类号： A61K51/00 ,  A61K39/395 ,  A61K38/19 ,  A61K38/20 ,  A61P35/00

    CPC分类号： A61K38/178 ,  A61K38/00 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6813 ,  A61K47/6849 ,  A61K49/0008 ,  A61K51/1027 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/732 ,  C07K2317/734 ,  C12N15/1138 ,  C12N2310/14 ,  A61K2300/00

    摘要： The present invention relates to a method to inhibit cancer by targeting CD24, more precisely a method to inhibit cancer by using CD24 expressed in most cancer cells as a target of an antibody therapeutic agent or by inhibiting the interaction between CD24 and P-selectin. CD24 is over-expressed in most cancer cells and CD24 accumulated in cytoplasm accelerates metastasis. Therefore, the method to inhibit cancer of the invention by targeting CD24 can be effectively used for the treatment of cancer by inhibiting the progress of various cancers over-expressing CD24.

    摘要翻译： 本发明涉及一种通过靶向CD24抑制癌症的方法，更确切地说，通过使用在大多数癌细胞中表达的CD24作为抗体治疗剂的靶标或通过抑制CD24和P-选择蛋白之间的相互作用来抑制癌症的方法。 CD24在大多数癌细胞中过度表达，并且在细胞质中累积的CD24加速转移。 因此，通过靶向CD24抑制本发明的癌症的方法可以通过抑制过表达CD24的各种癌症的进展而有效地用于治疗癌症。

    DATA PROCESSING, ANALYSIS METHOD OF GENE EXPRESSION DATA TO IDENTIFY ENDOGENOUS REFERENCE GENES
    5.
    发明申请
    DATA PROCESSING, ANALYSIS METHOD OF GENE EXPRESSION DATA TO IDENTIFY ENDOGENOUS REFERENCE GENES 审中-公开
    数据处理，基因表达数据分析方法鉴定内源性参考基因

    公开(公告)号：US20100137149A1

    公开(公告)日：2010-06-03

    申请号：US12521498

    申请日：2007-12-27

    申请人： Young Kee Shin ,  Mi Jeong Kwon ,  En Sel Oh ,  Yong Ho In ,  Sang Seok Koh

    发明人： Young Kee Shin ,  Mi Jeong Kwon ,  En Sel Oh ,  Yong Ho In ,  Sang Seok Koh

    IPC分类号： C40B30/02 ,  C40B40/08 ,  C12Q1/68 ,  G06F19/00

    CPC分类号： G16B25/00 ,  C12Q1/6813 ,  C12Q1/6851 ,  C12Q2600/166 ,  C12Q2545/113 ,  C12Q2545/101

    摘要： Disclosed are a data processing and analysis method of gene expression data for identifying endogenous reference genes and a composition for the quantitative analysis of gene expression, comprising a pair of primers and/or probes useful in the amplification of the identified endogenous reference genes. Introduced with the concepts of “Zero's proportion’ and CV, the me allows different datasets to be integrally analyzed, thereby searching for novel reference genes. By the method, 2,087 genes are first found as housekeeping genes which are expressed in most tissues, and the usefulness thereof in the relative quantification of different target genes is determined by analyzing their expression stability. Out of the 2,087 genes, 13 genes are found to show higher expression stability with lower expression levels across a wide range of samples than traditional reference genes such as GAPDH and ACTB, and therefore are suitable for the normalization of universal genes having relatively low expression levels.

    摘要翻译： 公开了用于鉴定内源参考基因的基因表达数据的数据处理和分析方法以及用于定量分析基因表达的组合物，其包含可用于扩增鉴定的内源性参考基因的一对引物和/或探针。 引入了“零比例”和CV的概念，我允许不同的数据集被整体分析，从而寻找新的参考基因。 通过该方法，首先发现2,087个基因作为在大多数组织中表达的管家基因，并且通过分析其表达稳定性来确定在不同靶基因的相对定量中的有用性。 在2087个基因中，发现13个基因在传统参考基因如GAPDH和ACTB的范围内，具有较高的表达水平，具有较高的表达水平，因此适用于表达水平相对较低的通用基因的标准化 。

    COMPOSITION FOR TREATMENT OF CERVIX CANCER
    7.
    发明申请
    COMPOSITION FOR TREATMENT OF CERVIX CANCER 有权
    用于治疗癌症的组合物

    公开(公告)号：US20100062051A1

    公开(公告)日：2010-03-11

    申请号：US12513337

    申请日：2007-11-05

    申请人： Young Kee Shin ,  Hun Soon Jung ,  Yu Kyoung Oh

    发明人： Young Kee Shin ,  Hun Soon Jung ,  Yu Kyoung Oh

    IPC分类号： A61K9/127 ,  A61K31/7088 ,  A61K33/24

    CPC分类号： C12N15/1131 ,  C12N2310/14 ,  C12N2320/31

    摘要： The present invention relates to a composition for the treatment of cervix cancer, more precisely a composition for the treatment of cervix cancer comprising the first active part containing human papilloma virus (referred as “HPV” hereinafter) specific siRNA as an active ingredient and the second active part containing an anticancer agent as an active ingredient. The composition for the treatment of cancer of the present invention has better anticancer effect than the single therapy of the HPV specific siRNA or the anticancer agent, and has an advantage of reducing side effects by using the anticancer agent at a low concentration.

    摘要翻译： 本发明涉及用于治疗宫颈癌的组合物，更确切地说，涉及用于治疗子宫颈癌的组合物，其包含含有人乳头瘤病毒（以下称为“HPV”）特异性siRNA作为活性成分的第一活性成分，第二 活性成分含有抗癌剂作为活性成分。 本发明的癌症治疗用组合物与HPV特异性siRNA或抗癌剂的单一治疗相比具有更好的抗癌作用，具有通过低浓度使用抗癌剂而降低副作用的优点。